• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Organon Cancels First Quarter Earnings Call

    4/29/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGN alert in real time by email

    Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company's April 26, 2026 announcement that it has entered into an agreement under which Sun Pharmaceutical Industries Limited will acquire Organon. Organon will issue its first quarter financial results on April 30, 2026 in a press release, as well as in a subsequent Form 10-Q that it will file with the U.S. Securities and Exchange Commission ("SEC").

    About Organon

    Organon (NYSE:OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women's Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

    Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

    Cautionary Note Regarding Forward-Looking Statements

    Except for historical information, this press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, Organon's proposed merger with Sun Pharmaceutical Industries Limited and the timing of Organon's release of first quarter 2026 financial information. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

    The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's filings with the SEC, including the company's most recent Annual Report on Form 10-K, the company's Current Report on Form 8-K, filed on April 27, 2026, and other SEC filings, available at the SEC's Internet site (www.sec.gov).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260429184636/en/

    Media Contacts:

    Karissa Peer

    (614) 314-8094

    Kate Vossen

    (732) 675-8448

    Investor Contacts:

    Jennifer Halchak

    (201) 275-2711

    Renee McKnight

    (551) 204-6129

    Get the next $OGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OGN

    DatePrice TargetRatingAnalyst
    4/28/2026$14.00Underweight → Neutral
    Piper Sandler
    12/9/2025$7.50Underweight
    Barclays
    10/27/2025$5.00Overweight → Underweight
    Piper Sandler
    5/2/2025Outperform → In-line
    Evercore ISI
    9/6/2024$18.00 → $20.00Neutral → Underweight
    JP Morgan
    11/3/2023$33.00 → $16.00Buy → Neutral
    Goldman
    9/21/2023$28.00Overweight
    Barclays
    3/16/2023$33.00Outperform
    Raymond James
    More analyst ratings

    $OGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and Corporate Controller Holzbaur Lynette bought $353,080 worth of shares (26,448 units at $13.35), increasing direct ownership by 100% to 52,851 units (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/7/26 10:02:30 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chair Cox Carrie Smith bought $501,755 worth of shares (65,400 units at $7.67) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    11/13/25 4:05:10 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cox Carrie Smith bought $100,591 worth of shares (12,469 units at $8.07) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/15/25 4:09:09 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Organon upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Organon from Underweight to Neutral and set a new price target of $14.00

    4/28/26 7:28:27 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Organon with a new price target

    Barclays initiated coverage of Organon with a rating of Underweight and set a new price target of $7.50

    12/9/25 8:51:54 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Organon from Overweight to Underweight and set a new price target of $5.00

    10/27/25 11:23:41 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organon to Present New Research on Access and Value at ISPOR 2026

    New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women's health and general medicines portfolio Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women's health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect O

    5/15/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Reports Results for the First Quarter Ended March 31, 2026

    First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma") in an all-cash transaction (the "merger"). The merger is expected to close in early 2027, subject to customary closing conditions, inc

    4/30/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

    SHANGHAI, April 29, 2026 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE:OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 "As the first, and currently the only, pertuzumab biosimilar in Europe, the EC's approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly  as breast cancer is the most commonly diagnosed cancer among women in the European Unio

    4/29/26 10:00:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SVP and Corporate Controller Holzbaur Lynette sold $353,080 worth of shares (26,448 units at $13.35) and acquired 46 shares, closing all direct ownership in the company (SEC Form 4)

    4/A - Organon & Co. (0001821825) (Issuer)

    5/7/26 4:00:40 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP and Corporate Controller Holzbaur Lynette bought $353,080 worth of shares (26,448 units at $13.35), increasing direct ownership by 100% to 52,851 units (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/7/26 10:02:30 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Drinane Juliana Papa

    4 - Organon & Co. (0001821825) (Issuer)

    4/2/26 4:26:12 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    SEC Filings

    View All

    SEC Form PREM14A filed by Organon & Co.

    PREM14A - Organon & Co. (0001821825) (Filer)

    6/1/26 6:03:46 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SD filed by Organon & Co.

    SD - Organon & Co. (0001821825) (Filer)

    5/29/26 6:00:14 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Organon & Co.

    10-Q - Organon & Co. (0001821825) (Filer)

    5/4/26 8:46:54 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Leadership Updates

    Live Leadership Updates

    View All

    Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

    Organon (NYSE:OGN) ("Organon" or "the company") today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Morrissey in his new role. Director Robert Essner will assume the role of Lead Independent Director. These appointments follow the resignation of Kevin Ali as Chief Executive Officer and member of the Board in connection with the Audit Committee investigation described below. Mr. Ali has agreed that he will not be entitled to severance o

    10/27/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Appoints Ramona A. Sequeira to the Company's Board of Directors

    Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac

    4/15/25 5:00:00 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO

    Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic Ovary Syndrome (PCOS), today announced that Colby Holtshouse has joined the Company as President and CEO. Colby brings a wealth of senior leadership and women's health expertise to the organization, having held executive positions with Organon (NYSE:OGN), Alydia Health, and Pel

    3/10/25 12:01:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Financials

    Live finance-specific insights

    View All

    Organon Reports Results for the First Quarter Ended March 31, 2026

    First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma") in an all-cash transaction (the "merger"). The merger is expected to close in early 2027, subject to customary closing conditions, inc

    4/30/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Cancels First Quarter Earnings Call

    Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company's April 26, 2026 announcement that it has entered into an agreement under which Sun Pharmaceutical Industries Limited will acquire Organon. Organon will issue its first quarter financial results on April 30, 2026 in a press release, as well as in a subsequent Form 10-Q that it will file with the U.S. Securities and Exchange Commission ("SEC"). About Organon Organon (NYSE:OGN) is a global

    4/29/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026

    Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will release its first quarter 2026 financial results on May 7, 2026, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the first quarter of 2026. Organon's first quarter results have not been finalized and are subject to the company's quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing First Quarter 2026 Financial R

    4/16/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Organon & Co. (Amendment)

    SC 13G/A - Organon & Co. (0001821825) (Subject)

    2/13/24 5:12:22 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Organon & Co. (Amendment)

    SC 13G/A - Organon & Co. (0001821825) (Subject)

    2/5/24 3:47:19 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Organon & Co. (Amendment)

    SC 13G/A - Organon & Co. (0001821825) (Subject)

    1/25/24 12:23:52 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care